Jane Street
VIRX

Jane Street’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Jane Street’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55,422
Closed -$8.92K – 11081
2024
Q4 		$8.92K Buy
+55,422
New +$10.9K ﹤0.01% 9187
2023
Q3 		– Sell
-41,854
Closed -$59K – 9555
2023
Q2 		$59K Sell
41,854
-13,611
-25% -$19.5K ﹤0.01% 8177
2023
Q1 		$88.2K Buy
55,465
+31,264
+129% +$56.8K ﹤0.01% 8282
2022
Q4 		$35.3K Buy
+24,201
New +$70.7K ﹤0.01% 8463
2020
Q3 		– Sell
-3,939
Closed -$36K – 8089
2020
Q2 		$36K Buy
+3,939
New +$59.4K ﹤0.01% 6912
2020
Q1 		– Sell
-304
Closed -$4K – 6130
2019
Q4 		$4K Buy
+304
New +$5.09K ﹤0.01% 4974
2015
Q3 		– Sell
-253
Closed -$160K – 4267
2015
Q2 		$160K Buy
+253
New +$134K ﹤0.01% 3331
2014
Q3 		– Sell
-61
Closed -$83K – 3161
2014
Q2 		$83K Buy
+61
New +$70.8K ﹤0.01% 2381
2013
Q4 		– Sell
-100
Closed -$104K – 2986
2013
Q3 		$104K Buy
+100
New +$107K ﹤0.01% 2541

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Jane Street's VIRX Position: Q1 2025 in Review

Jane Street sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 55,422 shares — an estimated $8.92K sold.

Jane Street first reported a position in VIRX in Q3 2013 and held it in 9 quarters. The position peaked at $160K in Q2 2015. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Jane Street reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Jane Street sold 55,422 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $8.92K.
  • Jane Street first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2013 and held it in 9 quarters.
  • Jane Street's Viracta Therapeutics, Inc. Common Stock position peaked at $160K in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.